Skip to main content
Fig. 2 | World Journal of Surgical Oncology

Fig. 2

From: Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma

Fig. 2

A, B Tumor recurrence and overall survival between patients with viral reactivation and without viral reactivation after PRFA for HBV-related hepatocellular carcinoma in the entire cohort. C, D Tumor recurrence and overall survival between patients receiving antiviral treatment (AVT) and not receiving AVT (non-AVT) after PRFA for HBV-related hepatocellular carcinoma. E, F Tumor recurrence and overall survival among three groups of patients receiving antiviral treatment (AVT), not receiving AVT with a low viral level (non-AVT-low) and not receiving AVT with a high viral level (non-AVT-high) after PRFA for HBV-related hepatocellular carcinoma (tumor recurrence: AVT vs. non-AVT-high, P < 0.001; AVT vs. non-AVT-low, P < 0.001; non-AVT-high vs. non-AVT-low, P = 0.037; overall survival: AVT vs. non-AVT-high, P < 0.001; AVT vs. non-AVT-low, P < 0.001; non-AVT-high vs. non-AVT-low, P = 0.046)

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us